Clinical trials: Nutrition Behavior
Prader-Willi Syndrome, Hyperphagia
Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
This Phase 2b/3 double-blind, placebo-controlled study will evaluate the safety, tolerability, and effects of livoletide on food-related behaviors in patients with Prader-Willi Syndrome (PWS).
- Trial name
- ZEPHYR (NCT03790865)
- Testing
- Livoletide
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 158 people
- Sponsor
- Millendo Therapeutics SAS
Obesity
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.
- Trial name
- NCT00603902
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 4,008 people
- Sponsor
- Eisai Inc.
Obesity
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of…
- Trial name
- NCT00395135
- Testing
- Lorcaserin 10 mg BID
- Where
- United States
- Volunteers
- 3,182 people
- Sponsor
- Eisai Inc.
Prader-Willi Syndrome
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
The purpose of this study was to evaluate the effects of a once daily subcutaneous injectable formulation of setmelanotide in obese participants with Prader-Willi syndrome on tolerability, weight loss, and hyperphagia-related…
- Trial name
- NCT02311673
- Testing
- Setmelanotide
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2…
- Trial name
- SURMOUNT-5 (NCT05822830)
- Testing
- Tirzepatide, Semaglutide
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 751 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program.
- Trial name
- SURMOUNT-3 (NCT04657016)
- Testing
- Tirzepatide
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 579 people
- Sponsor
- Eli Lilly and Company
Overweight and Obesity, Health Behavior
Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II
College students are in a newly independent phase of life; many of whom encounter unhealthy dietary decision- making, barriers to physical activity, and poor sleep behaviors.
- Conditions
- Overweight and Obesity, Health Behavior, Sleep Deprivation
- Trial name
- NCT02996864
- Testing
- Healthy Detours App, Fat Secret App
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist…
- Trial name
- SCALE™ IBT (NCT02963935)
- Testing
- liraglutide, CMS Intensive Behavior Therapy
- Where
- 10 sites in United States
- Volunteers
- 282 people
- Sponsor
- Novo Nordisk A/S
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Nutrition, Healthy, Behavior, Eating
Good Bowls: Eat Well At Work
The goal of this clinical trial is to improve the health of workers at their worksite by providing subsidized healthy meals supported by nutrition education and behavioral nudges using mobile health and Bluetooth technology.
- Trial name
- EWAW (NCT05776303)
- Testing
- Good Bowls, Good Bowls + App Nudges
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Equiti Food, LLC
Obesity, Overweight
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in treating obesity and leads to greater weight loss when given with a group lifestyle modification program…
- Trial name
- NCT00456521
- Testing
- Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Intensive group lifestyle modification counseling
- Where
- 9 sites in United States
- Volunteers
- 793 people
- Sponsor
- Orexigen Therapeutics, Inc